Physician profile
Daniel C Modarelli
NPI 1033179791
$3,059.26
in general payments reported to CMS, 2019-2025
28 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $27.92 · 2021: $74.39 · 2022: $434 · 2023: $201 · 2024: $1,122 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $367.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $319.07 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $291.92 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $278.13 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Novo Nordisk INC | $275.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $245.69 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $217.35 | 2022-2025 | |
| Lilly USA, LLC | $172.57 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $108.71 | 2022-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $101.89 | 2022-2025 | Spravato |
| Glaxosmithkline, LLC. | $93.90 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $84.16 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.35 | 2022-2025 | Xifaxan |
| Daiichi Sankyo INC. | $59.23 | 2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $55.21 | 2022-2025 | Camzyos, Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $44.90 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $44.70 | 2024-2025 | Voquezna |
| Antares Pharma, INC. | $43.50 | 2024-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $27.09 | 2022 | |
| Amneal Pharmaceuticals LLC | $23.27 | 2025 | Unithroid |
| Hologic Sales and Service, LLC | $21.94 | 2023 | Thinprep 2000 Processor |
| Xeris Pharmaceuticals, INC. | $21.71 | 2024 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $20.25 | 2024 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $19.74 | 2022 | |
| Horizon Therapeutics Plc | $17.03 | 2022 | |
| Medtronic, INC. | $15.32 | 2022 | |
| Viatris Specialty LLC | $14.16 | 2025 | Yupelri |
| Boston Scientific Corporation | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Modarelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.